Coronary Artery Disease Life Insurance Underwriting Guide

The Central Underwriting Idea

A stent or bypass does not cure atherosclerosis. It restores blood flow. The strongest case is therefore not simply "the procedure went well"; it is "the disease is stable, heart function is preserved, there is no current ischemia or angina, follow-up is consistent, and the major cardiovascular risk factors are well controlled."

For life insurance underwriting, the procedure is only part of the story. The underwriter is trying to understand the underlying coronary artery disease: how early it appeared, how much artery is involved, whether heart muscle was damaged, whether blood flow is now adequate, how well the heart pumps, whether symptoms or ischemia remain, and whether the applicant has changed the risk factors that caused the disease.

Can Someone With Coronary Artery Disease Qualify for Life Insurance?

Yes. Coronary artery disease (CAD) is one of the classic impaired-risk conditions, but it covers an enormous spectrum. A person with a single treated lesion, no heart attack, normal left-ventricular function, no symptoms and years of favorable follow-up can look very different to an underwriter from a younger applicant with diffuse multivessel disease, recurrent interventions, diabetes, smoking, ongoing angina or reduced ejection fraction.

Modern clinical care has also changed the risk landscape. PCI with stenting, CABG, aggressive lipid lowering, antiplatelet therapy, cardiac rehabilitation and better control of blood pressure, diabetes and smoking have improved outcomes. Current multisociety chronic-coronary-disease guidance emphasizes exercise, cardiac rehabilitation, lipid lowering and risk-factor management; a 2026 American Heart Association scientific statement stresses that secondary prevention remains essential after CABG because coronary disease can continue to progress even after successful surgery.

The Coronary-Artery-Disease Underwriting Sweet Spot

Older age at first diagnosis rather than premature CAD in the 30s or 40s.
Limited disease burden — for example, a single-vessel lesion rather than diffuse left-main or multivessel disease.
No myocardial infarction, or a remote infarction with preserved heart muscle function and no recurrent events.
Successful PCI/stent or CABG with no recurrent angina, restenosis, graft failure or repeat revascularization.
Left-ventricular ejection fraction (LVEF) in the normal range, with no heart-failure history or important wall-motion abnormality.
Favorable existing follow-up testing when clinically indicated, with no evidence of inducible ischemia and good functional capacity.
Nonsmoker, controlled blood pressure, aggressively managed LDL cholesterol, healthy activity level and good medication adherence.
No major adverse combination such as CAD plus poorly controlled diabetes, chronic kidney disease, significant peripheral vascular disease or prior stroke.

Why age at onset matters. CAD discovered at age 72 is not automatically "better" than CAD discovered at age 42, but premature disease can signal a stronger underlying atherosclerotic tendency and creates a much longer future exposure period. Underwriters therefore interpret the same anatomy differently depending on age, risk factors and the applicant's total cardiovascular history.

Start With the Disease — Not the Procedure

PCI, stents and bypass surgery are treatments for coronary artery disease. They are not separate diseases. NHLBI describes PCI as a catheter-based procedure that opens narrowed or blocked coronary arteries, often with a stent to help keep the vessel open. CABG creates a new route around blocked arteries using other blood vessels.

For underwriting, the key question is what remains after treatment. Was one focal lesion treated while the rest of the coronary tree was relatively clean? Or did the procedure treat only the most severe part of diffuse disease? Did the intervention occur because of stable angina, an acute heart attack, left-main disease or multiple blocked vessels? The answer can materially change expected mortality.

How early did CAD appear? Age at diagnosis and age at first MI, PCI or CABG.
How much disease is present? Number of vessels, exact arteries, lesion location and degree of stenosis; left-main/proximal disease matters.
Was heart muscle damaged? MI history, troponin/diagnosis, wall-motion findings and LVEF.
Is blood flow adequate now? Symptoms, clinically obtained stress/imaging results, angiography/CTA when available, and functional capacity.
Did disease recur? Restenosis, graft disease, recurrent angina, repeat PCI/CABG or new infarction.
Are the drivers controlled? Smoking, LDL, blood pressure, diabetes, weight, activity, kidney disease and medication adherence.

Blockages: Number, Location and Severity Matter

Coronary angiography and CT coronary angiography can show where plaque has narrowed the coronary arteries. Underwriting references traditionally distinguish nonobstructive from obstructive disease and pay close attention to the number of affected vessels, the degree of narrowing and how much myocardium is placed at risk.

A percentage by itself is not the whole answer. A proximal lesion in a major vessel can threaten more heart muscle than a distal lesion. Left-main disease and complex multivessel disease are particularly important. Current ACC/AHA guidance notes that CABG may be favored over PCI for selected patients with complex, diffuse multivessel disease when revascularization is required.

Minor/nonobstructive plaque, no ischemia — May represent lower disease burden, but still establishes atherosclerosis and requires risk-factor context.
Single-vessel focal disease — Potentially more favorable when successfully treated, especially with normal LVEF and no MI.
Two-vessel disease — More disease burden; age, lesion location, treatment and follow-up become increasingly important.
Three-vessel / diffuse disease — Higher long-term progression risk; CABG history, graft status, LVEF and risk-factor control are central.
Left-main or important proximal disease — Greater myocardium at risk; generally treated as a more significant CAD history.
Progressive/recurrent disease — Repeat stenosis, new lesions or repeat revascularization can materially worsen the underwriting picture.

Do not overread a single percentage. Clinical decisions about whether a lesion needs PCI or CABG are not based on stenosis percentage alone. Symptoms, ischemia, anatomy, physiology, comorbidities and overall coronary complexity matter. Underwriting should similarly avoid reducing the entire case to one number.

Stents and PCI: What Makes the Case Favorable?

A coronary stent is a small mesh device placed during PCI to hold an artery open. It can restore blood flow, relieve angina and reduce acute risk, but the applicant still has underlying atherosclerotic disease. Restenosis can occur, and antiplatelet therapy is commonly used after stenting to reduce thrombotic complications.

The strongest post-stent submission tells a complete story: why the PCI was performed, which artery was treated, whether there was an MI, how many stents were placed, what untreated disease remained, whether symptoms resolved, whether heart function is normal and whether subsequent clinical follow-up has been favorable.

One focal lesion; one successful PCI — Suggests a smaller anatomic disease burden than repeated or diffuse intervention.
No MI and normal LVEF — Less evidence of permanent myocardial injury.
No recurrent chest pain or ischemic symptoms — Supports clinical stability.
No restenosis or repeat PCI — Supports durable treatment response.
Excellent LDL/BP control; nonsmoker — Shows active secondary prevention of future atherosclerotic events.
Regular cardiology follow-up and medication adherence — Reduces uncertainty and supports durable risk-factor management.

Bypass Surgery (CABG): The Operation Is a New Beginning, Not a Cure

CABG routes blood around obstructed coronary arteries. It is commonly used when disease is extensive, involves multiple vessels or the left main coronary artery, or when anatomy is not well suited to PCI.

The underwriting challenge is that the operation itself often signals that the original CAD burden was substantial. The favorable story develops afterward: preserved ventricular function, no recurrent angina, no new infarction, stable graft/native-vessel status when clinically evaluated, good exercise tolerance and disciplined secondary prevention. The American Heart Association's 2026 update on secondary prevention after CABG emphasizes that CAD can continue to progress after surgery, highlighting LDL lowering, antiplatelet therapy when appropriate, smoking cessation, cardiometabolic risk reduction and cardiac rehabilitation.

Remote CABG, asymptomatic, normal LVEF, favorable clinical follow-up, excellent risk-factor control — Potentially favorable impaired-risk profile; age at onset and original disease burden still matter.
CABG plus prior MI but preserved LVEF and long stability — Often insurable in selected cases, but myocardial injury and event history generally add risk.
Repeat revascularization or recurrent angina after CABG — More concern for progressive native-vessel or graft disease.
CABG with diabetes, CKD, smoking or peripheral vascular disease — Multiple vascular risks can compound mortality beyond CAD alone.
CABG with persistently reduced LVEF or heart failure — Moves the case toward the cardiomyopathy/heart-failure risk spectrum and generally worsens insurability.

Heart Attack: Separate the Event From the Residual Damage

A myocardial infarction (MI) occurs when heart muscle is injured because blood flow is acutely reduced or blocked. A heart attack therefore adds information that a simple history of coronary stenosis does not: there has been an acute coronary event with potential permanent myocardial damage.

For underwriting, two applicants who both say "I had a heart attack" may be very different. One may have had rapid reperfusion, a small infarct, preserved LVEF and no residual ischemia. Another may have a large infarct, scar, reduced LVEF, ventricular arrhythmias or heart failure. The second profile carries substantially more risk even if both received a stent.

Time — More favorable: remote event with years of stability. More concerning: recent event or recurrent MI.
LVEF — More favorable: normal/preserved. More concerning: persistently reduced, especially ≤40%.
Symptoms — More favorable: no angina or heart-failure symptoms. More concerning: ongoing angina, dyspnea or functional limitation.
Ischemia — More favorable: no clinically demonstrated residual ischemia. More concerning: positive ischemic findings or new symptoms.
Rhythm — More favorable: no significant ventricular arrhythmia. More concerning: ventricular tachycardia, ICD or serious rhythm history.
Risk factors — More favorable: nonsmoker, LDL/BP/diabetes controlled. More concerning: smoking, poor adherence or multiple uncontrolled vascular risks.

Ejection Fraction: One of the Most Important Numbers in Cardiac Underwriting

Left-ventricular ejection fraction (LVEF) estimates the percentage of blood pumped out of the left ventricle with each contraction. The American Heart Association describes 50%–70% as a typical normal range, 41%–49% as mildly reduced/borderline, and 40% or less as reduced. EF is not the entire cardiac assessment, but in CAD it is a powerful summary of how much pumping function remains after ischemia or infarction.

50%–70% — Typical normal range. Supports a favorable case when anatomy, symptoms and follow-up are also favorable.
41%–49% — Mildly reduced / borderline. Adds concern for prior myocardial injury or ventricular dysfunction; trend and symptoms matter.
≤40% — Reduced. Often materially worsens mortality assessment and may overlap with heart-failure/cardiomyopathy underwriting.
Recovered EF — Improved from a prior low value. Potentially favorable trend, but the original cause, nadir, duration and stability of recovery remain important.

The trend matters. A current LVEF of 55% after a prior temporary decline is not necessarily interpreted the same way as an LVEF that has always been normal. Underwriters want the chronology: the lowest documented EF, the cause, treatment, recovery and how long the improvement has remained stable.

Stress Testing and Exercise Capacity: What Existing Results Can Tell the Underwriter

When clinically obtained, stress-test results can provide information about exercise capacity, symptoms, blood-pressure response and evidence of inducible ischemia. Insurance-medicine references have historically treated exercise duration/MET level, ST-segment changes, symptoms, perfusion defects, wall-motion abnormalities and ejection fraction as useful risk-stratification data.

A favorable existing test can strengthen a case, particularly when it demonstrates good functional capacity without ischemia or symptoms. But advisors should not tell an applicant to obtain medically unnecessary testing merely to improve an insurance submission. Current chronic-coronary-disease guidance specifically states that routine periodic anatomic or ischemic testing without a change in clinical or functional status is not recommended for clinical risk stratification. The practical underwriting approach is to collect the most recent clinically appropriate records that already exist.

Good exercise capacity; no chest pain — Supports functional stability.
No inducible ischemia on clinically indicated imaging — Supports adequate blood flow under stress.
Normal blood-pressure response and preserved LVEF — Supports favorable hemodynamic/ventricular function.
Early ischemia, poor exercise tolerance or hypotensive response — Raises concern for significant residual disease or impaired function.
Pharmacologic test because applicant cannot exercise — Interpret in context; inability to exercise may itself require explanation.

Risk-Factor Control Can Change the Story

CAD is a systemic atherosclerotic disease. Successful PCI or CABG treats important lesions, but long-term risk remains strongly influenced by smoking, LDL cholesterol, blood pressure, diabetes, kidney function, obesity, activity and medication adherence. This is one reason two applicants with identical procedure histories can receive different underwriting decisions.

Tobacco — Favorable: no current nicotine/tobacco use. Adverse: current smoking or relapse.
Lipids — Favorable: LDL aggressively managed, adherence documented. Adverse: persistently elevated LDL or poor adherence.
Blood pressure — Favorable: consistently controlled. Adverse: persistent uncontrolled hypertension.
Diabetes — Favorable: absent or well controlled without major complications. Adverse: poor control, nephropathy or vascular complications.
Kidney function — Favorable: stable/normal. Adverse: chronic kidney disease, especially with diabetes/CAD.
Activity — Favorable: regular activity/cardiac rehab when appropriate. Adverse: sedentary with functional limitation.
Other vascular disease — Favorable: none. Adverse: stroke/TIA, carotid or peripheral arterial disease.

Coronary Calcium Scores: Important for Screening, Different After Known CAD

Coronary artery calcium (CAC) scoring measures calcified plaque and can help estimate future coronary risk in people who do not already have established coronary disease. The American Heart Association notes that CAC testing is generally not the appropriate test for someone who already has known coronary artery disease or has had a heart attack, bypass or stent, because the diagnosis and treatment path are already established. CAC is an important concept for the broader heart-disease underwriting picture, but it should not be confused with the post-PCI/post-CABG assessment described here.

Illustrative Underwriting Direction After CAD, PCI, CABG or MI

The following is an educational framework, not a carrier quote. Actual underwriting varies by age, carrier, product, jurisdiction, time since event, anatomy, heart function, comorbidities and the complete medical record.

Older applicant; limited/single-vessel disease; no MI; normal LVEF; asymptomatic; favorable follow-up; nonsmoker; excellent risk-factor control — One of the strongest CAD profiles. Standard or relatively mild impairment may be possible in selected markets; preferred treatment is carrier- and age-specific and should never be assumed.
Remote single PCI/stent; no MI; no restenosis; normal LVEF; no ischemic symptoms — Potentially favorable after an appropriate stability period, especially at older ages and with strong secondary prevention.
Remote CABG; stable for years; normal LVEF; no angina; favorable clinical follow-up — Often insurable in selected cases; original multivessel burden and age at surgery remain important.
Prior MI with preserved LVEF, no recurrent ischemia and long stability — Potentially insurable, but the infarction generally adds mortality risk beyond uncomplicated CAD.
Multiple interventions, recurrent stenosis, diabetes/CKD, smoking or reduced LVEF — Increasingly likely to require a significant rating; combined impairments can compound risk.
Recent MI/PCI/CABG, active angina, pending cardiac evaluation, progressive disease or markedly reduced LVEF — Often postponed until recovery/evaluation is complete; severe persistent disease may be declined depending on facts and carrier.

Timing is not one universal clock. Many field guides historically postpone immediately after MI or revascularization, but there is no single market-wide waiting period. The underwriter needs enough time and follow-up to know that recovery is complete, treatment is stable and no early recurrence or complication is emerging. The more serious the original disease, the more important durable stability becomes.

The Advisor's Coronary-Artery-Disease Checklist

Current age and age at first CAD diagnosis
Exact event history: angina, MI/STEMI/NSTEMI, cardiac arrest or incidental CAD
Dates of every PCI/angioplasty/stent and CABG procedure
Coronary anatomy: number of vessels, exact arteries, degree/location of stenosis and left-main involvement
Number and location of stents; any restenosis or stent thrombosis
CABG details: number of grafts and any later graft/native-vessel disease when documented
Any recurrent angina, shortness of breath, heart-failure symptoms or functional limitation
Most recent LVEF and prior lowest LVEF; include echocardiogram or nuclear report when available
Existing clinically obtained stress-test results: exercise time/METs, symptoms, ischemia, perfusion or wall-motion findings
Latest cardiology note and whether any testing or procedure is currently pending
Blood pressure history and current control
Lipid profile, especially LDL, and current lipid-lowering therapy
Tobacco/nicotine history and quit date
Diabetes status and A1C if applicable
Kidney function and any chronic kidney disease
Other vascular disease: carotid disease, TIA/stroke, peripheral arterial disease or aneurysm
Current cardiac medications and evidence of adherence
Cardiac rehabilitation participation and current exercise/activity level
Family history of premature cardiovascular disease
Any arrhythmia, pacemaker/ICD, valve disease or cardiomyopathy that should cross-link to later heart-series articles

Submission strategy. For a difficult CAD case, the goal is not to hide the diagnosis. It is to make the chronology unmistakable: what happened, how severe it was, how it was treated, what heart function is now, what follow-up shows, and what the applicant has done to reduce future risk. A complete cardiology record can prevent an underwriter from having to assume the worst.

Sources

American College of Cardiology / American Heart Association and partner societies, 2023 Guideline for the Management of Patients With Chronic Coronary Disease
American Heart Association, "Secondary Prevention After Coronary Artery Bypass Graft Surgery: 2026 Update"
National Association of Independent Life Brokerage Agencies (NAILBA), Field Underwriting Guide, Version 4.0, Coronary Artery Disease section
Academy of Life Underwriting, ALU 201 Intermediate Medical Life Insurance Underwriting, Chapter 13
National Heart, Lung, and Blood Institute (NHLBI/NIH), Coronary Heart Disease Treatment and Stents resources
National Heart, Lung, and Blood Institute (NHLBI/NIH), Coronary Artery Bypass Grafting resources
American Heart Association, Heart Attack Treatment and Cardiac Procedures/Surgeries resources
American Heart Association and NHLBI heart-attack resources
American Heart Association, "HF and Your Ejection Fraction Explained"
American Heart Association, "Coronary Artery Calcium Test"
Reinsurance Group of America (RGA), Coronary Artery Disease Resource Hub

This article is educational only and is not medical, legal, tax or insurance advice. It is not an offer, quote or promise of eligibility or rate class. Underwriting guidelines, reinsurance practices, products and pricing vary by insurer, jurisdiction, age and individual facts and can change without notice. Historical field-guide examples are included only to illustrate how underwriting frameworks have been expressed and should not be treated as current carrier commitments. The issuing carrier makes the final underwriting decision. Applicants should answer all questions completely and truthfully and make medical decisions with licensed healthcare professionals. Advisors should not recommend medically unnecessary testing solely for insurance underwriting.

Coronary Artery Disease and Life Insurance Underwriting